<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03328312</url>
  </required_header>
  <id_info>
    <org_study_id>36325348/2017</org_study_id>
    <nct_id>NCT03328312</nct_id>
  </id_info>
  <brief_title>Combined Use of Low-dose Sugammadex Plus Neostigmine Administered for Reversal of Rocuronium</brief_title>
  <official_title>A Randomized, Blinded, Prospective Study of the Combined Use of Low-dose Sugammadex Plus Neostigmine Administered for Reversal of Rocuronium-induced Neuromuscular Block in Obese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iuliu Hatieganu University of Medicine and Pharmacy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Iuliu Hatieganu University of Medicine and Pharmacy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reversal of rocuronium-induced neuromuscular block by the combination of low-doses of&#xD;
      neostigmine plus sugammadex decreases the cost of anesthetic medications, while maintaining&#xD;
      efficacy of reversal in obese patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background Neuromuscular paralysis is a frequent requirement to facilitate airway management&#xD;
      and surgery. Patients receiving neuromuscular blocking agents (NMBAs) are at risk of residual&#xD;
      neuromuscular blockade (RNMB) that can lead to postoperative cardio-pulmonary complications,&#xD;
      and may increase postoperative morbidity and mortality.1-2 NMBAs can be antagonized with the&#xD;
      cholinesterase inhibitor neostigmine; however, this agent has several undesirable side&#xD;
      effects because of its parasympathetic stimulation.3 Thus, muscarinic receptor antagonists,&#xD;
      such as atropine, are used along with cholinesterase inhibitors; however, these drugs also&#xD;
      have their own set of adverse effects. Despite its relatively slow onset of action and&#xD;
      inability to antagonize profound blockade, neostigmine is still used frequently for reversal&#xD;
      of rocuronium-induced neuromuscular blockade because of its low cost. Sugammadex is a&#xD;
      selective relaxant biding agent, developed to encapsulate the steroidal NMBAs, and proved to&#xD;
      be extremely effective for the reversal of either shallow (dose of 2 mg/kg), deep (dose of 4&#xD;
      mg/kg), or even profound (dose of 16 mg/kg) neuromuscular blockade. However, routine use of&#xD;
      sugammadex is limited by its relatively high cost compared with neostigmine.&#xD;
&#xD;
      The purpose of the study is to investigate drug costs and adverse effects of low-dose&#xD;
      neostigmine (0.025 mg/kg) plus low-dose sugammadex (1 mg/kg) for reversal of&#xD;
      rocuronium-induced neuromuscular block, and compare efficacy of antagonism and costs of this&#xD;
      combination therapy with the current standard therapies: full-dose sugammadex (2 mg/kg) and&#xD;
      full-dose neostigmine (0.05 mg/kg) plus atropine.&#xD;
&#xD;
      Randomization and blinding On randomization, each patient will be allocated by a unique&#xD;
      identifying number into study groups &quot;A&quot;, &quot;B&quot;, or &quot;C&quot;. The allocation of a patient to the&#xD;
      specific group will be only known by the research assistant. The participating anaesthetists&#xD;
      as well as the research staff who collect patient data will remain blinded until after the&#xD;
      completion of the study.&#xD;
&#xD;
      For reversal of rocuronium neuromuscular- block we used:&#xD;
&#xD;
        -  Group A - Sugammadex (Bridion®) 2 mg/kg,&#xD;
&#xD;
        -  Group B - Neostigmine (Miostin®; Stigmosan®) 0.05 mg/kg and atropine 1 mg/ dose.&#xD;
&#xD;
        -  Group C - Neostigmine (Miostin®; Stigmosan®) 0.025 mg/kg and atropine 0.5 mg/dose&#xD;
           followed within 3 min by Sugammadex 1 mg/kg.&#xD;
&#xD;
      Monitoring the neuromuscular blockade After induction of anesthesia and before administration&#xD;
      of rocuronium, monitoring of neuromuscular blockade at the adductor pollicis muscle is&#xD;
      initiated using acceleromyography (TOF-Watch SX, Organon, Dublin, Ireland). After degreasing&#xD;
      the skin, two surface electrodes are placed above the ulnar nerve near the wrist. After&#xD;
      induction of general anesthesia, 50-Hz tetanic stimulation is applied for 5 sec and followed&#xD;
      after 1 min by train-of-four (TOF) stimulation every 15 sec. If the response to TOF is&#xD;
      stable, calibration and supramaximal stimulation are ensured by built-in calibration function&#xD;
      (CAL2). After at least 2 min of a stable baseline documentation of the response to TOF,&#xD;
      rocuronium is administered.&#xD;
&#xD;
      At the end of surgery, inhalational agent (sevoflurane) will be discontinued. Once the&#xD;
      end-tidal concentration of sevoflurane reaches 0.4-0.6%, the previously randomized reversal&#xD;
      study drug will be administrated at shallow neuromuscular block (TOF count of 2). The primary&#xD;
      efficacy variable is the incidence of residual neuromuscular block (defined as TOFR &lt;0.90)&#xD;
      measured at least 15 min. after the administration of the reversal agent. In case of residual&#xD;
      block, a rescue dose of 2 mg/kg sugammadex will be administrated before tracheal extubation.&#xD;
      Extubation is performed once patient is deemed fully recovered (TOFR = 1.0)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">December 1, 2017</start_date>
  <completion_date type="Anticipated">June 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of postoperative residual curarization (PORC)</measure>
    <time_frame>24 hours</time_frame>
    <description>Incidence of postoperative residual curarization (PORC) (defined as a train-of-four ratio, TOFR &lt;0.9) measured 15 min after administration of the reversal agent.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time</measure>
    <time_frame>24 hours</time_frame>
    <description>1. Time period from administration of the reversal agent until recovery of TOFR to &gt;0.90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bradycardia</measure>
    <time_frame>24 hours</time_frame>
    <description>2. Number of bradycardic episodes (HR &lt;60 bpm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual blockade</measure>
    <time_frame>24 hours</time_frame>
    <description>3. Incidence of clinical symptoms potentially associated with residual neuromuscular blockade (diplopia, difficulty swallowing, feeling of general weakness)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Incidence of Postoperative Residual Curarization</condition>
  <arm_group>
    <arm_group_label>Sugammadex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For reversal of rocuronium neuromuscular- block we will use Sugammadex</description>
  </arm_group>
  <arm_group>
    <arm_group_label>neostigmine+atropine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>For reversal of rocuronium neuromuscular- block we will use Neostigmine (Miostin®; Stigmosan®) 0.05 mg/kg and atropine 1 mg/ dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>neostigmine+atropine+sugammadex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For reversal of rocuronium neuromuscular- block we will use Neostigmine (Miostin®; Stigmosan®) 0.025 mg/kg and atropine 0.5 mg/dose followed within 3 min by Sugammadex 1 mg/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>Time period from administration of the reversal agent to recovery of TOFR &gt;0.9</description>
    <arm_group_label>Sugammadex</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>neostigmine+atropine</intervention_name>
    <description>Number and time of bradycardic episodes (HR&lt;60 bpm) as well as that of tachycardic episodes (HR&gt;100 bpm) before tracheal extubation</description>
    <arm_group_label>neostigmine+atropine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>neostigmine+atropine+sugammadex</intervention_name>
    <description>4. Time of extubation</description>
    <arm_group_label>neostigmine+atropine+sugammadex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients scheduled for elective abdominal surgery&#xD;
&#xD;
          -  16-65 years of age&#xD;
&#xD;
          -  BMI 30-39.9 ( obese class I-II)&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) physical status II.&#xD;
&#xD;
          -  Surgery scheduled for general anesthesia and tracheal intubation and planned&#xD;
             extubation at the end of surgery&#xD;
&#xD;
          -  Surgical procedures with an anticipated length of at least 60 min.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Emergency surgery&#xD;
&#xD;
               -  Patients unable to consent to study participation&#xD;
&#xD;
               -  Patients expected to be maintained on mechanical ventilation postoperatively&#xD;
&#xD;
               -  Contraindication to any of the study drugs&#xD;
&#xD;
               -  Patients with existing neuromuscular disease&#xD;
&#xD;
               -  Acute or chronic renal failure (GFR-EPI &lt;30 mL/min/1.73 m2)&#xD;
&#xD;
               -  Acute/chronic liver disease (Child-Pugh Score &gt;1)&#xD;
&#xD;
               -  Hyperkalemia (&gt; 5.3 mmol/l)&#xD;
&#xD;
               -  Pregnancy&#xD;
&#xD;
               -  History of stroke or ongoing paresis&#xD;
&#xD;
               -  Glaucoma&#xD;
&#xD;
               -  Breast feeding&#xD;
&#xD;
               -  Sepsis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caius Breazu, Md,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Iuliu Hatieganu University of medicine and pharmacy cluj-Napoca</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Calin I Mitre, MD,PhD</last_name>
    <phone>004074157497</phone>
    <email>cmitre2001@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caius M Breazu, MD,PhD</last_name>
    <phone>0040743010012</phone>
    <email>csbreazu@yahoo.com</email>
  </overall_contact_backup>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>October 17, 2017</study_first_submitted>
  <study_first_submitted_qc>October 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2017</study_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Iuliu Hatieganu University of Medicine and Pharmacy</investigator_affiliation>
    <investigator_full_name>Breazu Caius Mihai</investigator_full_name>
    <investigator_title>Assistant professor MD,PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delayed Emergence from Anesthesia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atropine</mesh_term>
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

